NCT05418959
Genetic Risk Stratification of Pediatric Skin Lesions
Enrolling by Invitation
PHASE1Ages 0–20InterventionalDiagnosticMassachusetts General HospitalInvestigator-initiated
~100 participants
Updated 2026-05-22 on ClinicalTrials.gov
What's tested:DermTech PLA noninvasive adhesive biopsy
At a glance
Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Presence or absence of PRAME genetic marker.
Measured over 1 day
+1 more outcome measured
Conditions
Where it's being run
1 sites across 1 statesMassachusetts1
Study leadership
- Elena B Hawryluk, MD, PhD · PRINCIPAL_INVESTIGATOR · Massachusetts General Hospital
Who to contact
This trial hasn't published a contact. View it on ClinicalTrials.gov
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
20 years of age or younger.
Subjects or parents willing and able to give informed consent, and assent as appropriate
Patients will have one or more atypical skin lesions with management plan of monitoring, surgical biopsy, and/or excision of atypical nevi within the next 6 months
Exclusion
Lesions on palms, soles, mucosal membranes, or area where hair cannot be trimmed
Bleeding or ulcerated lesions
Previously biopsied, scarred, or known melanoma lesions
Presence of active psoriasis/eczema/other skin condition in area to be biopsied
What this trial measures
- Presence or absence of PRAME genetic marker.1 day
Presence or absence of PRAME genetic marker from PLA test
- Presence or absence of LINC genetic marker.1 da7
Presence or absence of LINC genetic marker from PLA test